



Electronic patient-reported outcomes in chronic kidney disease

Nicola Anderson¹✉, Derek Kyte², Christel McMullan¹, Paul Cockwell³,
Olalekan L. Aiyegbusi¹, Ravinder Verdi⁴ and Melanie J. Calvert¹

Considerable research and investment have focused on the use of electronic patient-reported outcomes (ePROs) in nephrology. However, systematic collection of ePROs to inform the care of patients with chronic kidney disease remains sporadic. A change in culture is needed to encourage their wider adoption in clinical practice.

Patients with chronic kidney disease (CKD) often report a high symptom burden that has a considerable negative impact on their health-related quality of life (HRQoL)¹. Information on symptoms and HRQoL can be obtained from patients using validated, psychometrically robust questionnaires. Responses have traditionally been collected on paper, but there is increasing interest in the digital collection and real-time use of electronic patient-reported outcomes (ePROs). Data on ePROs offer unique insights: in clinical trials they can provide valuable evidence on the efficacy and tolerability of treatments and in routine clinical care they can be used to deliver personalized care and to assist auditing and benchmarking to improve services². Increasing evidence from specialities such as oncology indicates that use of ePROs in routine care is a cost-effective method of improving clinician–patient communication, enhancing symptom management, reducing hospitalizations and improving HRQoL and overall survival^{3,4}. Yet, despite some prioritization at a national policy level, routine collection of ePROs to inform kidney care is limited.

Current use and evidence of benefit

The majority of healthcare systems do not report routine collection of ePROs for patients with CKD. However, in Denmark, a generic web-administered ePRO system known as AmbuFlex is used to manage kidney outpatient follow-up⁵. Key areas of ePRO research in nephrology include outcome selection, which should be aligned with recommended core outcome sets; the development of outcome measures, including assessment of their reliability, validity and ability to detect change; and the feasibility and acceptability of ePRO use for patients¹. However, clinicians have highlighted a lack of empirical evidence on the efficacy of use of ePROs in kidney care as a reason for slow adoption into routine practice⁶.

Several studies are exploring the effectiveness of ePROs in kidney care. For example, the Australian SWIFT study is a registry-based, cluster randomized controlled trial (RCT) that is investigating the effect of 3 monthly

ePRO symptom monitoring with clinician feedback over 12 months on HRQoL; secondary outcomes are overall survival, symptom severity, healthcare utilization and cost effectiveness⁷. In Canada, the EMPATHY pragmatic multi-centre cluster RCT will implement and evaluate the use of disease-specific and generic ePRO monitoring with linked treatment aids for clinicians and patient information handouts⁸. The primary outcome of this study is patient–provider communication assessed using a communication assessment tool. Both SWIFT and EMPATHY are focusing on in-centre haemodialysis populations.

In the UK, the OPT-ePRO study developed an intervention that utilizes existing infrastructure to securely collect, transfer and display ePRO data across all stages of CKD and treatment modalities⁹. An evaluation of this intervention in routine practice is planned. The RePROM pilot trial demonstrated the feasibility of a RCT of ePRO symptom monitoring in patients with advanced CKD¹⁰. The intervention comprised real-time integration of ePRO symptom data into the electronic health record with automated alerting of the clinical team when participants reported severe symptoms. The preliminary findings suggest that healthcare utilization was lower in the ePRO group than in the control group. These data will inform a future RCT aimed at exploring the efficacy and cost-effectiveness of the ePROs intervention.

Real-world implementation

Successful implementation of ePROs in real-world settings requires a clear understanding of the patient population, the purpose of ePRO collection and pathways for clinical responses. Although RCTs provide valuable evidence, contextual factors that can subvert implementation efforts in real-world settings must be considered.

Barriers to collection and use of ePROs include poor clinician ‘buy-in’, which is associated with difficulty in integrating ePROs into existing digital systems, impact on workflow, anxiety about interpretation and inability to effectively deal with responses⁶. Commonly reported facilitators of ePRO use include ‘champions’ who have

¹Centre for Patient Reported Outcomes Research, NIHR Birmingham Biomedical Research Centre and NIHR Applied Research Collaboration West Midlands, University of Birmingham, Birmingham, UK.

²School of Allied Health and Community, University of Worcester, Worcester, UK.

³Department of Nephrology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

⁴Patient Partner, University of Birmingham, Birmingham, UK.

✉e-mail: NEA451@bham.ac.uk

<https://doi.org/10.1038/s41581-022-00619-3>

the time and knowledge to explain the potential importance of ePROs to colleagues and patients⁶. The complexity of decisions involved in treating kidney disease highlights the importance of shared decision making in nephrology, and ePROs can support this model of care. Within a high-pressure clinical environment, clinicians could potentially act as gatekeepers to ePRO use by controlling access to systems and review of data; a change in culture is required to address this issue. A systematic case needs to be made that ePROs can enhance workflow efficiency and improve patient care. Support from international and national professional societies and integration of ePROs into clinical service specifications is required to facilitate their widespread adoption.

Potential unintended consequences of ePRO use include worsening of healthcare inequalities due to a lack of access to digital devices, single-language systems and the poor health literacy of some patients. Care must also be taken to communicate directly with patients about what their results mean for them rather than over-digitizing the patient experience by acting on raw scores alone. Effective patient and public involvement at all stages of ePROs implementation from measure selection to system evaluation can mitigate some of these issues. Non-context-specific facilitators of ePRO use include access to resources to guide their use, such as those collated by the **PROTEUS consortium**, which was formed to optimize the use of patient-reported outcomes in research studies and clinical practice.

Future directions

Use of new technologies, such as computer adaptive testing, which generates specific questionnaires for each individual based on their previous responses, could reduce the burden of ePRO collection for patients⁶. In addition, application programming interfaces that enable secure exchange of data can be used to facilitate linkage and aggregation of ePROs data across platforms, potentially including electronic health records and registries.

CKD is heterogeneous, and subtype-specific outcome measures may be required. However, in our opinion, ePROs methodology should concentrate on standardization of domains and items in questionnaires to enable effective comparison and multiple usage of the collected data, with further investigation of the psychometric properties of existing measures to improve their interpretation, rather than the development of new questionnaires. Better understanding of individual ePRO scores and changes over time, including minimal clinically important differences, will assist clinical decision making. Trust in the ability of ePROs to enhance risk stratification when used alongside other data will increase uptake and improve shared decision making, particularly when used to inform choice of treatment.

In addition to general guidance on score interpretation, understanding of the true meaning of ePROs can only be undertaken through discussion with patients. To facilitate such conversations, data must be presented in a clear and informative way. The use of clinical dashboards and the addition of ePROs to other forms of data in these dashboards can augment patient–provider communication.

The COVID-19 pandemic has led to a huge increase in the use of telemedicine. It is important to design ePRO systems that can support sustainable healthcare programmes, making best use of resources including time and infrastructure. Studies are needed to investigate the cost effectiveness of use of ePROs in kidney care and to calculate their other impacts, including the potential carbon savings associated with reduced clinic visits, transport and healthcare utilization as a result of use of ePROs to manage and triage outpatient activity.

Optimized use of ePROs can strengthen the patient voice in routine kidney care, but effective implementation requires more than research efforts and interest from the nephrology community. A willingness to change culture and to consider ePRO data to be equal in value and complementary to other forms of health data, including clinical outcomes, is required to deliver truly patient-centred care.

1. Fletcher, B. R. et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. *PLoS Med.* **19**, e1003954 (2022).
2. Schick-Makaroff, K. et al. An evidence-based theory about PRO use in kidney care: a realist synthesis. *Patient* **15**, 21–38 (2021).
3. Basch, E. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *J. Am. Med. Assoc.* **318**, 197–198 (2017).
4. Lizée, T. et al. Cost-effectiveness of web-based patient-reported outcome surveillance in patients with lung cancer. *J. Thorac. Oncol.* **14**, 1012–1020 (2019).
5. Schougaard, L. M. V. et al. AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases. *Qual. Life Res.* **25**, 525–534 (2016).
6. Anderson, N. E. et al. Using patient-reported outcome measures during the management of patients with end-stage kidney disease requiring treatment with haemodialysis (PROM-HD): a qualitative study. *BMJ Open* **11**, e052629 (2021).
7. Greenham, L. et al. The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis. *Trials* **23**, 419 (2022).
8. Johnson, J. A. et al. A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in Hemodialysis care (EMPATHY): a study protocol. *BMC Health Serv. Res.* **20**, 731 (2020).
9. Van Der Veer, S. N. et al. Developing an intervention to implement electronic patient-reported outcomes in renal services in the UK. *Stud. Health Technol. Inform.* **270**, 936–940 (2020).
10. Kyte, D. et al. Results of a pilot feasibility randomised controlled trial exploring the use of an electronic patient-reported outcome measure in the management of UK patients with advanced chronic kidney disease. *BMJ Open* **12**, e050610 (2022).

Competing interests

N.A. receives funding from the National Institute for Health and Care Research (NIHR) and personal fees from GlaxoSmithKline (GSK) outside the submitted work. M.J.C. is director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, director of the Centre for Patient Reported Outcomes Research and a NIHR senior investigator. M.J.C. receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR Applied Research Collaboration (ARC) West Midlands, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, SPINE UK, UKRI, UCB Pharma, Janssen, GSK and Gilead. M.J.C. has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. D.K. reports grants from Macmillan Cancer Support, Innovate UK, the NIHR, NIHR Birmingham BRC, and NIHR SRMRC, and personal fees from Merck and GSK outside the submitted work. C.M. receives funding from the NIHR SRMRC, the NIHR Birmingham-Oxford BTRU in Precision Transplant and Cellular Therapeutics, and Innovate UK, and has received personal fees from Aparito Ltd outside the submitted work. O.L.A. receives funding from the NIHR BRC, NIHR ARC, West Midlands, NIHR Birmingham-Oxford BTRU in Precision Transplant and Cellular Therapeutics, Innovate UK, Gilead Sciences Ltd, Janssen Pharmaceuticals, Inc. and Sarcoma UK. O.L.A. declares personal fees from Gilead Sciences Ltd, GSK and Merck outside the submitted work. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

RELATED LINKS

Proteus Consortium: <https://theproteusconsortium.org/>